42 results about "Connexin" patented technology

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to define the effect of connexin43 in the cardiac hypertrophy process caused by myocardial cell hypertrophy induced by pathological matrix stiffness and pressure overload, the invention provides application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the application disclosed by the invention, the Connexin43 gene is found to be used as a potential target for preventing or treating myocardial fibrosis for the first time, and a myocardial cell hypertrophy process induced by pathological matrix hardness and a myocardial hypertrophy process caused by overload of pressure can be relieved by knocking down the expression of the Connexin43 gene or inhibiting the semi-channel activity of the Connexin43. Therefore, the inhibitor targeting the Connexin43 gene can be used for preparing the medicine for preventing or treating the myocardial fibrosis, and a new way is provided for treating the myocardial fibrosis.

The invention discloses a method for promoting ovulation of sexual maturity zebrafish by using Gap27, and relates to the technical field of artificial breeding of fish, a gap connecting protein inhibitor Gap27 is applied to ovulation induction of zebrafish, an intercellular communication network in follicles is accurately intervened, the problem of asynchronous ovulation is solved, and in the final stage of maturation of oocytes, ovulation of sexual maturity zebrafish is promoted. Close substance and information exchange is carried out among follicular granule cells through a gap connecting channel formed by connecting protein Cx43, and Gap27 is used as a specific peptide fragment, can simulate an extracellular ring structure of Cx43, and competitively binds with Cx43 on an adjacent cell membrane, so that formation and functions of the gap connecting channel are physically blocked, and the follicular granule cells are separated from each other. When ovarian tissues of sexually mature female fish are exposed in a Gap27 solution, the transmission of inhibitory signals from granular cells to oocytes can be effectively interrupted, the rupture of nuclear membranes of the cells is promoted, and the final maturation process is completed.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine nano preparation and application thereof in preparation of a medicine for preventing / treating PM2.5 induced lung injury. The invention provides a traditional Chinese medicine nano preparation. The traditional Chinese medicine nano preparation comprises nobiletin, formononetin and a carrier. According to the traditional Chinese medicine nano preparation, the nobiletin and the formononetin are entrapped in the carrier to form the nano particles with uniform particle size and good dispersity, so that the problems of poor water solubility and low bioavailability of the medicine can be effectively improved, the lung targeted delivery is enhanced, and the residence time of the medicine in the lung is prolonged. According to the traditional Chinese medicine nano preparation, the expression of ZO-1, OCLN, E-cad and other connexins is remarkably improved by inhibiting the EGFR pathway, the alveolar epithelial barrier structure and function are protected, and the inflammatory response and oxidative stress induced by PM2.5 are relieved, so that the lung injury induced by PM2.5 is effectively prevented and treated.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.

This invention relates to a recombinant adeno-associated virus (rAAV) vector encoding connexin 26 (CX26). The invention further relates to the use of the AAV vector in the treatment of hereditary hearing loss.

The present disclosure relates to pharmaceutical compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, optionally for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

The present invention relates to a recombinant adeno-associated virus (rAAV) vector encoding a connexin 26 (CX26). The invention also relates to the use of said AAV vector in the treatment of hereditary hearing loss.

The present invention relates to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, in rescuing or restoring retinal function, rescuing or restoring retinal structure, and / or rescuing or restoring choroidal structure and / or function in chronic retinal disorders and other disorders.

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a myocardial targeted engineered extracellular vesicle as well as a preparation method and application thereof. The invention provides an engineered extracellular vesicle. The engineered extracellular vesicle is an engineered extracellular vesicle subjected to overexpression modification of gap junction protein alpha 1; the amino acid sequence of the gap connecting protein alpha 1 is shown as SEQ ID NO. 1. The engineered extracellular vesicles are modified by expression gap connecting protein alpha1, and compared with a control, the engineered extracellular vesicles modified by the gap connecting protein alpha1 are more ingested by myocardial cells, have higher heart targeting performance and can provide targeting drug carriers for patients with heart diseases. The invention provides a new drug research and development approach and means for clinical treatment of heart failure or myocardial injury, also provides a heart targeted modification tool for industrial research and development and basic scientific research users, and has very important medicinal value.

The present invention relates to the use of a direct antibody, with a high degree of affinity and specificity, against the extracellular domain of the hemichannels formed by connexin 26 (Cx26, encoded by GJB2), connexin 30 (Cx30, encoded by GJB6) and / or connexin 32 (Cx32, encoded by GJB1), to treat brain tumours and epilepsy correlated thereto or to reduce or inhibit the development thereof.

The invention relates to a connexin-related kinase 1 (AAK1) inhibitor of a compound shown in a general formula (I), a preparation method thereof and application of the connexin-related kinase 1 (AAK1) inhibitor in medicine.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to clarify the effect of pan-connexin1 in the cardiac hypertrophy process caused by overload of pressure, the invention provides application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the invention, it is found for the first time that Pannexin1 is an effective target spot for treating myocardial hypertrophy caused by pressure overload, and an expression inhibitor for inhibiting Pannexin1 by targeting the target spot can be used for preparing drugs for treating myocardial hypertrophy caused by pressure overload. Therefore, the invention provides the application of the inhibitor targeting the Pannexin1 gene in preparation of the medicine for preventing or treating the myocardial fibrosis, and a new treatment mode is provided for treatment of the myocardial fibrosis.

The invention discloses a method for increasing the yield of astaxanthin in phaffia rhodozyma by using a synergistic gene expression strategy. Firstly, the invention relates to application of a non-homologous terminal connection protein gene and an iron reductase gene in improving the yield of astaxanthin in phaffia rhodozyma; the method comprises the following steps: introducing a non-homologous terminal junction protein gene and an iron reductase gene into phaffia rhodozyma cells, cooperatively expressing the non-homologous terminal junction protein gene and the iron reductase gene, and fermenting by using the phaffia rhodozyma to produce the astaxanthin. According to the method disclosed by the invention, the biomass and the astaxanthin yield of the phaffia rhodozyma are improved by synergistically overexpressing the non-homologous terminal connecting protein and the iron reductase gene in phaffia rhodozyma cells; the phaffia rhodozyma high-yield astaxanthin strain is constructed through a gene overexpression technology, has the characteristics of genetic characters and stable astaxanthin fermentation yield, and is relatively high in feasibility.

During aging, egg cells exhibit gradual loss of adherin complexes. The absence of connexin ultimately results in premature separation of sister staining monomers, resulting in aneuploidy. The inventors have designed an artificial adhesion system that binds staining monomers or chromosomes by forming complexes, thereby reducing the phenomena of premature separation of age-related sister staining monomers, e.g., in egg cells. The artificial adhesion system is a complex, and the aneuploidy risk is reduced by binding chromosomes or dyeing monomers. The complex comprises (I) one or more first proteins and (II) one or more second proteins wherein: (I) the first protein and (II) the second protein each comprise (i) a chromatin binding component, (ii) a protein binding region located at the N-terminus of the chromatin binding component, (Hi) a protein binding region located at the C-terminus of the chromatin binding component. The invention also includes nucleic acid molecules encoding the complexes. In addition, several in vitro methods associated with the complexes or nucleic acid molecules encoding said complexes also constitute part of the invention.

The invention belongs to the technical field of medicines, and provides a medicine capable of preventing and treating gastric ulcer. Evaluation of the acute gastric ulcer treatment effect of early chick embryo amniotic fluid finds that the early chick embryo amniotic fluid can reduce the gastric tissue ulcer area and inflammatory factor infiltration, and the protective effect of the mucosal barrier on the gastric tissue is enhanced by reducing the calcium ion content in the gastric tissue and myeloperoxidase, so that the gastric ulcer treatment effect is improved. In addition, the oxidative stress level caused by ethanol is obviously inhibited, and the level of tight junction protein of stomach tissue is up-regulated. The invention has the potential of treating gastric ulcer.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in a patient whose age is, for example, at least 2 years old, or at least 12 years old. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

Disclosed herein are methods and materials for treating myocarditis with gene therapy. In some cases, disclosed herein are methods and material for treating myocarditis in a subject in need thereof comprising administering to the subject an effective amount of a vector comprising a nucleic acid sequence encoding a connexin 43 polypeptide operably linked to a promoter active in cardiac muscle tissue. Also disclosed herein are methods of treating myocarditis by administering to a subject an agent that increases the level of a connexin 43 encoding nucleic acid molecule or connexin 43 polypeptide.

The present disclosure provides compositions and methods for treating osteosarcoma, such as osteosarcoma in a patient who has previously received at least one first-tier osteosarcoma treatment but has failed treatment. The methods comprise promoting the opening of Cx43 hemichannels in bone cells by, for example, using a composition comprising an anticonnexin 43 antibody.

The inventions relate to compounds and compositions comprising connexin modulators and their use in dose regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.

The invention relates to the technical field of biology, and provides an application of a connexin signal channel in regulating and controlling the body weight and the body shape of worker bees. According to the invention, a cascade regulation pathway of Jhe-JH-Titin in bees is disclosed for the first time, which indicates that Jhe (juvenile hormone esterase) regulates JH (juvenile hormone) and further regulates the expression of Titin (connexin) to influence the growth and development of bees, and finally regulates the body type and weight of worker bees of bees. By means of the method, the purposes of regulating and controlling the birth weight and the body type of worker bees can be achieved. According to the method, molecular breeding work is carried out by adopting the regulation and control effect of the Jhe-JH-Titin pathway on the body type of the bees, the traditional breeding period can be shortened, and the breeding target of improving the body type of the bees can be rapidly achieved. The method is simple, convenient, easy to operate and short in breeding period, the body length of worker bees can be rapidly increased only through one generation, the breeding cost can be effectively reduced, and the method has important application and popularization value for bee breeding.

Provided is a method, a kit, and a device for determining whether there is incidence of dementia or whether there is a risk of onset of dementia in a human subject using a biomarker that allows highly sensitive and specific determination by a simple operation. The method includes the step of calculating the ratio(s) between the expression level(s) of the connexin 43 gene and / or the prolyl hydroxylase domain-containing protein 3 gene, and the expression level of the connexin 37 gene.

Methods for identifying compounds that positively regulate connexin 43 hemichannels.

The invention discloses a method for increasing the yield of astaxanthin in phaffia rhodozyma by using a non-homologous terminal junction protein gene. Firstly, the invention relates to application of a non-homologous terminal connection protein gene in improving the yield of astaxanthin in phaffia rhodozyma; according to the method, non-homologous terminal connexin genes are introduced into phaffia rhodozyma cells, non-homologous terminal connexin is independently expressed, and then fermentation treatment is performed by using phaffia rhodozyma to produce astaxanthin. According to the method disclosed by the invention, the biomass of phaffia rhodozyma and the yield of astaxanthin are improved by independently overexpressing the non-homologous terminal junction protein gene in phaffia rhodozyma cells; the phaffia rhodozyma high-yield astaxanthin strain is constructed through a gene overexpression technology, has the characteristics of genetic characters and stable astaxanthin fermentation yield, and is relatively high in feasibility.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and their use for the treatment of certain diseases, disorders, defects and conditions, including for the treatment of cells and subjects that contain shortened telomeres or that are in need of or may benefit from telomere extension, telomerase activity and / or telomerase reverse transcriptase activity, as well as for the treatment of cells and subjects for telomere-related diseases and / or telomere -related medical conditions, including cell senescence and cognitive decline. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro, ex vivo or in vivo, and kits including the compounds or compositions and instructions for use.

In accordance with various aspects of the present disclosure, the disclosure relates to a method of treating cancer comprising (a) administering to a subject an anti-tight junction protein-1 antibody; (b) determining a PRO-C3 level in a test sample from the subject; and (c) comparing the level of PRO-C3 in the test sample to the level of PRO-C3 in a control sample. In some aspects, if the level of PRO-C3 in the test sample is not reduced relative to the level of PRO-C3 in the control sample, the dose of an anti-tight connexin-1 antibody administered to the subject is increased. In some aspects, if the level of PRO-C3 in the test sample is reduced relative to the control sample, the dose of an anti-tight connexin-1 antibody administered to the subject is not increased.

The inventions relate to compounds, compositions and kits comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and new and improved methods comprising systemic and topical administration of such modulators for the treatment of ocular and dermatological diseases, disorders and conditions, including ocular and dermatological diseases, disorders and conditions characterized at least in part by inflammasome-mediated inflammationb.